Corpus ID: 53543814

Bioequivalence between two Prolonged Release Tablets of Desvenlafaxine Succinate in Healthy Subjects under Fasting and Fed Conditions

@inproceedings{CFP2018BioequivalenceBT,
  title={Bioequivalence between two Prolonged Release Tablets of Desvenlafaxine Succinate in Healthy Subjects under Fasting and Fed Conditions},
  author={Vespasiano CFP and Accennato VAC and M. Riccio and AC Noboli},
  year={2018}
}
  • Vespasiano CFP, Accennato VAC, +1 author AC Noboli
  • Published 2018
Bioavailability in different formulations of desvenlafaxine100 mg prolonged release tablets was compared in two bioequivalence studies, one under fasting conditions and the other after a standard breakfast. Both studies were single dose, randomized, open label, twoperiod crossover, with Brazilian male and female healthy subjects. Blood samples were taken during 48 h and plasmatic concentrations were determined using a validated UPLC-MS/MS method. Confidence intervals (CI90%) for the peak plasma… Expand

Figures and Tables from this paper

References

SHOWING 1-7 OF 7 REFERENCES
Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery
  • 14
Drug–drug interactions involving antidepressants: focus on desvenlafaxine
  • 4
  • PDF
Resolution n ° 1170 , of April 19 , 2006 . Guide for tests of relative bioavailability / bioequivalence of medicines
  • Applied Biopharmaceutics & Pharmacokinetics
  • 2005